IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Arrow Pharmaceuticals Pty Ltd v Novartis AG [2019] APO 22
Patent Application: 2013204752
Title:Pharmaceutical compositions containing an S1P modulator
Patent Applicant: Novartis AG
Opponent: Arrow Pharmaceuticals Pty Ltd
Delegate: Dr Leslie F. McCaffery – Deputy Commissioner of Patents
Decision Date: 10 May 2019
Hearing Date: 21 November 2018, in Canberra
Catchwords: PATENTS – request for consideration of a document pursuant to regulation 5.23 – the balance of considerations lies with refusal of the request – section 59 – opposition to the grant of a patent – grounds of clarity, fair basis, manner of manufacture, inventive step – section 40 – the claims are clear – the claims are fairly based –– the claims define a manner of manufacture – utility – the promise of the invention has been met – inventive step – claims lack inventive step –– costs awarded – applicant provided 2 months from the date of the decision to propose amendments.
Representation: Counsel for the applicant: Christian Dimitriadis SC
Solicitor for the applicant: Clayton Utz
Patent attorney for the applicant: Davies Collison Cave
Counsel for the opponent: Claire Cunliffe
Patent attorney for the opponent: Jones Tulloch
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2013204752
Title:Pharmaceutical compositions containing an S1P modulator
Patent Applicant: Novartis AG
Date of Decision: 10 May 2019
DECISION
The opposition by Arrow Pharmaceuticals Pty Ltd is successful on the ground of inventive step.
Claims 1 to 15 lack inventive step.
The opposition is unsuccessful on the grounds of utility, manner of manufacture, fair basis and clarity.
Costs are awarded against Novartis AG.
Novartis AG given 2 months from the date of this decision to propose amendments.
REASONS FOR DECISION
Patent Application 2013204752 (the Application) was filed by Novartis AG (the Applicant) on 12 April 2013. The application is a divisional of Australian application 2011235934, which lapsed without gaining acceptance. 2011235934 is itself a divisional of Australian application 2007302296, which also lapsed without gaining acceptance. The present application claims earliest priority of 26 September 2006. This was not in dispute so I do not need to go into any further detail on the priority of the present claims. There are also a number of other related applications, but nothing turns on this point so I will not consider these any further.
Examination was requested on 12 April 2013. The application was advertised accepted on 27 October 2016. A notice of opposition was filed by Arrow Pharmaceuticals Pty Ltd (the Opponent) on 27 January 2017.
The statement of grounds and particulars (SGP) was filed on 27 April 2017. This set out the following grounds of opposition: manner of manufacture, novelty, inventive step, usefulness, full description, fair basis and clarity. An amendment of the SGP was filed on 27 July 2017 and allowed on 17 August 2017. A further request for an amendment of the SGP was filed on 21 December 2017 to add bibliographic details of a document that the Opponent became aware…
Keep reading for free
Create a free CaseChat account to read Arrow Pharmaceuticals Pty Ltd v Novartis AG and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2019] APO 22
- Decision Date
CaseChat Overview and Summary
The Applicant filed a patent application in relation to pharmaceutical compositions containing an S1P modulator. The Applicant sought to patent solid pharmaceutical compositions suitable for oral administration in the form of a tablet or a capsule, comprising a specific weight of the S1P receptor modulator 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol, in free form or in a pharmaceutically acceptable salt form, and microcrystalline cellulose (MCC) in the absence of a sugar alcohol. The Applicant argued that fingolimod, its structure, properties and uses were not common general knowledge at the relevant time. The Opponent argued that the claims were obvious in view of the common general knowledge and in view of the common general knowledge combined with the prior art. The Opponent also argued that the invention was not useful, was not a manner of manufacture, lacked a fair basis, and lacked clarity. The Opponent requested that additional evidence be considered under Regulation 5.23, but this was refused.
The court first considered the request to consider additional evidence. The evidence in question was considered unlikely to be crucial to the decision, and the balance of considerations lay against it. The evidence was therefore not considered under Regulation 5.23.
The court then considered the issue of inventive step. The problem was the provision of a stable oral dosage form of an S1P receptor modulator. The court considered fingolimod was not common general knowledge at the relevant time and therefore was not part of the starting point. The invention was therefore inventive in view of the common general knowledge alone. The court considered that the skilled person would reasonably be expected to have ascertained Chavez, a media release summarising the results of a completed Phase II study of fingolimod for the treatment of relapsing multiple sclerosis, in view of the problem. The court considered that the skilled person would have proceeded to prepare formulations as described by Dr Williams in view of the common general knowledge and Chavez. The court considered that the claims lacked inventive step in view of Chavez. The court considered that the skilled person would reasonably be expected to have ascertained Chiba, a patent disclosing the use of fingolimod as an immunosuppressive agent, in view of the problem. The court considered that the skilled person would have proceeded to prepare formulations as described by Dr Williams in view of the common general knowledge and Chiba. The court considered that the claims lacked inventive step in view of Chiba. The court considered that the skilled person would not reasonably be expected to have ascertained Oomura, a patent describing formulations comprising S1P modulators for oral administration, in view of the problem. The court considered that the skilled person would not reasonably be expected to have ascertained Matsumori, a patent describing treatment of viral disease using fingolimod, in view of the problem. The court therefore concluded that the claims lacked inventive step.
The court then considered the other grounds of opposition. The court considered that the promise of the invention was that the compositions provide a convenient means of systemic administration of S1P receptor agonists and other modulators, do not suffer from the disadvantages of liquid formulations for injection or oral use, and have good physicochemical and storage properties. The court considered that the Opponent had not made out their case that the claimed invention had failed to attain the promise of the invention. The court considered that the claims defined a manner of manufacture. The court considered that the claims were fairly based. The court considered that the claims were clear.
The court concluded that the opposition was successful on the ground of inventive step. The opposition was unsuccessful on the other grounds. The Applicant was given two months from the date of the decision to propose amendments. The court awarded costs to the Opponent.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.